Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Pascal Vranckx
Dual Antiplatelet Therapy Duration in Patients at High Bleeding Risk : A Systematic Review and Meta-Analysis
Dual Antiplatelet Therapy Duration in Patients at High Bleeding Risk: A Systematic Review and Meta-Analysis Key Points Question Among patients at high bleeding risk (HBR) undergoing percutaneous coronary intervention (PCI), is an abbreviated dual antiplatelet therapy (DAPT) regimen safer and as effective as standard DAPT duration?
One- versus three-month dual antiplatelet therapy in high bleeding risk patients undergoing percutaneous coronary intervention for non-ST-segment elevation acute coronary syndromes
DOI: 10.4244/EIJ-D-23-00658 Davide Cao1,2, MD; Pascal Vranckx3, MD; Marco Valgimigli4,5, MD, PhD; Samantha Sartori1, PhD; Dominick J. Angiolillo6, MD, PhD; Sripal Bangalore7, MD, MHA; Deepak L. Bhatt1, MD, MPH; Yihan Feng1, MS; Junbo Ge8, MD; James Hermiller9, MD; Raj R. Makkar10, MD; Franz-Josef Neumann11, MD, PhD; Shigeru Saito12, MD; Hector Picon13, MD; Ralph Toelg14, MD; Aziz Maksoud15, MD; Bassem M. Chehab16, MD; James W. Choi17, MD; Gianluca Campo18, MD; José M.
Geographical variations in the effectiveness and safety of abbreviated or standard antiplatelet therapy after PCI in patients at high bleeding risk
These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.
What’s New in the European ACS Guidelines and How Will My Practice Change?
Faculty: Overview This live roundtable discussion, chaired by Prof Rob Storey (University of Sheffield, Sheffield, UK), addresses the 2023 ACS guideline updates that were recently presented at the European Society of Cardiology (ESC) annual meeting in Amsterdam.
Individualising Antithrombotic Strategies for Established Coronary Artery Disease
Faculty: Reserve your Seat Overview Chaired by Prof Marco Valgimigli (Instituto Cardiocentro Ticino, Lugano, CH), this live broadcast will address the importance of providing individualised treatment in Acute Coronary Syndrome (ACS) and Chronic Coronary Syndrome (CCS). We will start by reviewing the two patient cases presented in phase one of this programme by Prof Eliano Navarese (Nicolaus Copernicus University PL) and Prof Pascal Vranckx (Hartcentrum Hasselt, BE).
Pascal Vranckx | Radcliffe Cardiology
Biography Prof Pascal Vranckx is a Clinical Consultant in Interventional Cardiology and Medical Director of Cardiac Critical Care Services at the Hartcentrum Hasselt in Belgium, and Professor of Medicine at the University of Hasselt, Belgium. Prof Vranckx is also board member of the European Cardiovascular Research Institute, in Rotterdam, The Netherlands.
Where Do Potent P2Y12 Inhibitors Fit Into Current Practice?
Key Learning Objectives Following the completion of this programme, physicians will be in a position to: Apply the use of validated bleeding risk tools across a wide range of patients Use guidelines and clinical judgement to select antiplatelet therapy regimens in patients at elevated bleeding risk Recall the clinical significance of trial data assessing truncated periods of DAPT Prescribe confidently in patients judged to be at elevated bleeding risk Recall the safety profiles of different...
Abbreviated Antiplatelet Therapy After Coronary Stenting in Patients With Myocardial Infarction at High Bleeding Risk:
JACC Journals › JACC › Archives › Vol. 80 No. 13 Abstract Background The optimal duration of antiplatelet therapy (APT) after coronary stenting in patients at high bleeding risk (HBR) presenting with an acute coronary syndrome remains unclear. Objectives The objective of this study was to investigate the safety and efficacy of an abbreviated APT regimen after coronary stenting in an HBR population presenting with acute or recent myocardial infarction.
The Significance of Drug–Drug and Drug–Food Interactions of Oral Anticoagulation
Login or register to view PDF. Abstract Vitamin K antagonists (VKAs) such as warfarin are the most commonly prescribed oral anticoagulants worldwide. However, factors affecting the pharmacokinetics of VKAs, such as food and drugs, can cause deviations from their narrow therapeutic window, increasing the bleeding or thrombosis risk and complicating their long-term use.
Antithrombotic treatment strategies after PCI - Authors' reply
1 Vranckx P Valgimigli M Eckardt L et al. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. Lancet. 2019; 394: 1335-1343 Thomas Gremmel and Kurt Huber, as well as Johann Auer and colleagues, contribute to this valuable discussion.
Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial
Summary Background We aimed to assess the safety of edoxaban in combination with P2Y12 inhibition in patients with atrial fibrillation who had percutaneous coronary intervention (PCI). Methods ENTRUST-AF PCI was a randomised, multicentre, open-label, non-inferiority phase 3b trial with masked outcome evaluation, done at 186 sites in 18 countries.
Dyspnoea in the GLOBAL LEADERS trial - Authors' reply
We thank David Martí and Marcelo Sanmartín for their interest in GLOBAL LEADERS. 1 Vranckx P Valgimigli M Juni P et al. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. Lancet.
Critical Appraisal of Contemporary Clinical Endpoint Definitions in Coronary Intervention Trials
The Academic Research Consortium (ARC) and the Standardized Data Collection for Cardiovascular Trials Initiative have recently published updated clinical and angiographic endpoint definitions for percutaneous coronary intervention trials. The aim of this document is to provide practical guidance to facilitate and harmonize the implementation of those definitions in randomized trials or registries, as well as to foster consistency among independent adjudication committees.
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la
We hypothesised that ticagrelor, in combination with aspirin for 1 month, followed by ticagrelor alone, improves outcomes after percutaneous coronary intervention compared with standard antiplatelet regimens. GLOBAL LEADERS was a randomised, open-label superiority trial at 130 sites in 18 countries.
Dual Antiplatelet Therapy Challenges in Complex Clinical Scenarios
Case 1: Many Stents, An Emergency, and Now What? Doctor Bernard Chevalier Case Description Case 1 was a male with risk factors for dyslipidaemia and hypertension for which he was taking fluvastatin and ramipril, respectively. He had no significant comorbidity. His angina was symptomatic and was Canadian Cardiovascular Society (CCS) Grade III but had been stable for 3 months. Thallium scintigraphy had shown anterior and septal ischaemia and an EF of 58% at rest that reduced to 50% at stress.
Combined anatomical and clinical factors for the long-term risk stratification of patients undergoing percutaneous coronary intervention: the Logistic Clinical SYNTAX score | European Heart Journal
Background The SYNTAX score (SXscore), an anatomical-based scoring tool reflecting the complexity of coronary anatomy, has established itself as an important long-term prognostic factor in patients undergoing percutaneous coronary intervention (PCI). The incorporation of clinical factors may further augment the utility of the SXscore to longer-term risk stratify the individual patient for clinical outcomes.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Pascal
Contact Pascal, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack